Is there a difference in clinical behavior between urothelial carcinoma of the upper urinary tract and that of the lower urinary tract? What is the risk of developing tumors in the contralateral and lower urinary tracts in patients presenting initially with an upper urinary tract cancer? Conversely, what is the risk of developing an upper urinary tract tumor in patients who initially present with a lower urinary tract tumor?
Urothelial neoplasms involving the upper urinary tract are uncommon, accounting for about 5% of primary urothelial neoplasms. Unlike tumors involving the lower urinary tract (mostly urinary bladder), more than 50% of them are of high grade and high stage (pT2 or higher) and typically require radical surgery such as nephrectomy or ureterectomy with or without nephrectomy. The risk of developing carcinoma in the contralateral kidney is 1%–3%.The projected incidence of a tumor in the contralateral kidney rises progressively from 2.7% to 6.5% during a follow-up from 5 years to 15 years, respectively. The incidence of bladder carcinoma subsequent to an upper tract carcinoma ranges from 9% to 48%. Bladder cancer is also significantly more common among patients with bilateral upper tract cancer. This high risk is probably due to both spreading of the original cancer and field changes (new cancer). For patients presenting with bladder cancer, the risk for developing upper tract cancer is 1%–4%.
KeywordsBladder Cancer Bladder Tumor Renal Pelvis Transitional Cell Carcinoma Urothelial Carcinoma
Unable to display preview. Download preview PDF.
- 1.Murphy WM, Beckwith JB, Farrow GM (1994) Tumors of the kidney, bladder, and related urinary structures. Fascicle 11, 3rd series. In: Rosai J, Sobin LH (eds) Atlas of tumor pathology. Armed Forces Institute of Pathology, Washington, DC, pp 313–321.Google Scholar
- 6.Dudak SC, Soloway MS, Neulander EZ (2000) Management of upper tract transitional cell carcinoma: surgical management. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds) Comprehensive text-book of genitourinary oncology. Lippincott Williams & Wilkins, Philadelphia, pp 367–376.Google Scholar
- 8.Anonymous (2002) Renal pelvis and ureter. In: Greene FL, Page DL, Fleming ID, Fritz AG, Blech CM, Haller DG, Morrow M (eds) AJCC cancer staging manual. Springer-Verlag, New York, pp 329–331.Google Scholar
- 12.Reuter VE (2004) The urothelial tract: renal pelvis, ureter, urinary bladder, and urethra. In: Mills SE (ed) Sternberg’s Diagnostic Surgical Pathology. Lippincott Williams & Wilkins, Philadelphia, pp 2035–2081.Google Scholar
- 14.Huffman JL (2000) Management of upper tract transitional cell carcinomas: endoscopic management In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds) Comprehensive textbook of genitourinary oncology. Lippincott Williams & Wilkins, Philadelphia, pp 367–376.Google Scholar
- 17.IARC (1979) IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans. Supplement 1. Chemicals and industrial processes associated with cancer in humans. International Agency for Research on Cancer, Lyon.Google Scholar
- 18.US DHEW (1979) Smoking and health: a report of the Surgeon General. PHS Publ 79-50066. Department of Health, Education and Welfare, Washington, DC.Google Scholar
- 20.Bladder Cancer (1981) In: Skrabanek P, Walsh, A (eds) UICC technical report series, vol 60. UICC, Geneva, pp 118–143.Google Scholar
- 21.Dominick MA, White MR, Sanderson TP, Van Fleet T, Cohen SM, Arnold LE, Cano M, Tannehill-Gregg S, Moehlenkamp JD, Waites CR, Schilling BE (2006) Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol 34: 903–920.PubMedCrossRefGoogle Scholar
- 26.Lynch HT, Taylor RJ, Lynch JF, Knezetic JA, Barrows A, Fodde R, Wijnen J, Wagner A (2003) Multiple primary cancer, including transitional cell carcinoma of the upper uroepithelial tract in a multigeneration HNPCC family: molecular genetic, diagnostic, and management implications. Am J Gastroenterol 98: 664–670.PubMedCrossRefGoogle Scholar
- 45.Schwalb DA, Herr HW, Sogani PC, Russo P, Sheinfeld J, Fair WR (1992) Upper tract disease following intravesical BCG for superficial bladder cancer: five year follow-up. J Urol 147(suppl):273A.Google Scholar